Galmed Pharmaceuticals Ltd.NASDAQ: GLMD

Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol

Jan 4, 2023 · Issued by Galmed Pharmaceuticals Ltd.

Histological improvement in fibrosis (≥1 stage) was demonstrated in 39% of subjects according to NASH CRN, in 61% of subjects by ranked assessment with a highly statistically significant (p